Drug Profile
Cusatuzumab - argenx
Alternative Names: Anti-CD70 SIMPLE Antibody; ARGX-110; JNJ 74494550; JNJ-4550Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator arGEN-X
- Developer argenx; Cilag GmbH International
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD70 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Cutaneous T-cell lymphoma; Myelodysplastic syndromes
- Phase I/II Haematological malignancies; Solid tumours
- No development reported Autoimmune disorders; Nasopharyngeal cancer
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, First-line therapy) in Japan (IV)
- 28 May 2023 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, First-line therapy) in Japan (IV)
- 27 Mar 2023 Cusatuzumab licensed to OncoVerity worldwide